Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCO-101 + paclitaxel
- Development stage
- Unknown
- Lead developer
- Scandion Oncology
- Modality
- Small Molecules
- Administration
- Oral (SCO-101), Intravenous (paclitaxel)
01
Overview
**SCO-101 + paclitaxel** is a combination regimen investigated specifically to overcome chemotherapy resistance in cancers such as pancreatic ductal adenocarcinoma (PDAC). SCO-101 is an oral small molecule that inhibits the SRPK1 enzyme, blocks the ABCG2 drug transporter (associated with multi-drug resistance), and inhibits the liver enzyme UGT1A1. Paclitaxel is a widely used microtubule inhibitor that suppresses cancer cell division. Preclinical studies have shown that the combination of SCO-101 and paclitaxel synergistically increases cytotoxicity in paclitaxel-resistant PDAC cells. In a phase Ib trial, the combination's toxicity, pharmacokinetics, and maximum tolerated dose were evaluated, demonstrating manageable safety signals but no clear added efficacy in clinical endpoints. The primary indication under study for this combination is pancreatic cancer refractory to taxane chemotherapies[1].
- Brand names
- Taxol
- Other names
- SCO-101SCO101SCO 101SC0191SC-0191SC 0191paclitaxel
02
Targets
UGT1A1 (UDP-glucuronosyltransferase 1A1)SRPK1 (Serine/arginine-rich protein-specific kinase 1)TUBB (Tubulin (alpha and beta subunits))ABCG2 (Breast cancer resistance protein)
Beyond the preview
Go deeper on SCO-101 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCO-101 + paclitaxel.